Imbalance in PB IL-17-Secreting and Regulatory Cells in Pars Planitis Is Associated with Dysregulation of IFN-γ-Secreting Cells, Especially in Patients with Clinical Complications

Table 1

Inclusion criteria for screening procedure as well as inclusion and exclusion criteria for study enrolment.

Inclusion criteria for screening
years old; Written informed consent; Diagnosis of intermediate uveitis according to SUN criteria
Inclusion criteria	Exclusion criteria
Written informed consent; Established diagnosis of pars planitis: (i) Negative viral tests (for HSV-1 and HSV-2, VZV, HHV-7, CMV, Epstein-Barr virus, and HIV); (ii) Negative blood IgG and IgM levels for Borrelia burgdorferi, Toxoplasma, Toxocara, and Bartonella pertussis; (iii) Negative QuantiFERON and skin reaction to tuberculin (Mantoux test with tuberculin RT23); (iv) Negative blood test for syphilis (Wassermann reaction and VDRL test); (v) No previous diagnosis of systemic autoimmune disease; (vi) No pathologic findings in X-ray examination of the chest; Patient’s observation for at least the time necessary to establish the diagnosis of pars planitis including diagnostic tests and other specialist consultation (for at least 4 weeks)	or >70 years old; No written consent; Noncompliance with the medical monitoring (study protocol); Pregnancy and breast feeding; Diabetes mellitus; Hypertension; Neoplastic disorder (diagnosed or suspected); Life-threatening diseases; Oral or local steroid treatment in the last 4 weeks; Oral or local immunomodulatory treatment in the last 6 months (such as methotrexate, azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine, or cyclophosphamide); Any previous biological treatment (e.g., adalimumab, infliximab, rituximab, and anakinra)